Annual report [Section 13 and 15(d), not S-K Item 405]

BUSINESS COMBINATION (Details 1)

v3.26.1
BUSINESS COMBINATION (Details 1) - BioCorRx Pharmaceuticals, Inc [Member]
12 Months Ended
Dec. 31, 2025
Risk-free interest rate 3.96%
Expected term (years) 2 years
Expected volatility 161.00%
Expected dividends 0.00%